# The associations between leisure sedentary behaviors, physical activity and chronic respiratory diseases: a Mendelian randomization study

#### Keywords

Physical activity, Mendelian randomization, Leisure sedentary behaviors, Chronic respiratory disease

#### Abstract

#### Introduction

Chronic respiratory diseases represent a significant global health burden, characterized by high incidence and mortality rates. However, the potential link between physical activity, leisure sedentary behavior, and susceptibility to chronic respiratory diseases remain uncertain.

#### Material and methods

A two-sample Mendelian randomization approach was used in this investigation, using physical activity and leisure sedentary behavior as exposures, and common chronic respiratory diseases such as asthma, bronchiectasis, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, pulmonary arterial hypertension, and obstructive sleep apnea syndrome as outcomes, to explore the genetic causal relationships. We utilized genome-wide association studies to select genetic instrumental variables related to these exposures. These variables were then used to assess the impact of physical activity and leisure sedentary behavior on the susceptibility to chronic respiratory diseases.

#### Results

Our findings indicate that strenuous sports or other exercises and vigorous physical activity are protective factors against asthma, whereas leisure television watching is a risk factor. Frequent leisure Television watching is closely associated with an increased susceptibility to chronic obstructive pulmonary disease. Computer using during leisure time and overall acceleration average in physical activity are inversely related to the risk of developing pulmonary arterial hypertension. Higher engagement in driving and vigorous physical activity are causally linked to a reduced risk of obstructive sleep apnea syndrome.

#### Conclusions

In summary, our analysis confirms the causal relationships between physical activity, sedentary behavior, and chronic respiratory diseases, providing genetic evidence that supports lifestyle modifications to reduce susceptibility to these conditions.

# 1The associations between leisure sedentary behaviors, physical activity and chronic2respiratory diseases: a Mendelian randomization study

- 3 Yuxin Zou <sup>1#</sup>, Manyi Pan <sup>1#</sup>, Huaqi Guo <sup>1\*</sup>
- 4 1 Department of Respiratory and Critical Care Medicine, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of

5 Medicine, Shanghai, China.

- 6
- 7 <sup>#</sup> These authors contributed equally to this work.
- 8 \* Corresponding author.
- 9

#### 10 **Corresponding to:**

- 11 Huaqi Guo, PhD
- 12 Department of Respiratory and Critical Care Medicine, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of
- 13 Medicine, 200011, Shanghai, China.
- 14 E-mail: guohuaqi814102@163.com.

#### 15 Abstract

Background: Chronic respiratory diseases represent a significant global health burden, characterized by high incidence and mortality rates. However, the potential link between physical activity, leisure sedentary behavior, and susceptibility to chronic respiratory diseases remain uncertain.

Methods: A two-sample Mendelian randomization approach was used in this investigation, using physical activity 19 and leisure sedentary behavior as exposures, and common chronic respiratory diseases such as asthma, bronchiectasis, 20 chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, pulmonary arterial hypertension, and obstructive 21 sleep apnea syndrome as outcomes, to explore the genetic causal relationships. We utilized genome-wide association 22 studies to select genetic instrumental variables related to these exposures. These variables were then used to assess the 23impact of physical activity and leisure sedentary behavior on the susceptibility to chronic respiratory diseases. 24 Results: Our findings indicate that strenuous sports or other exercises and vigorous physical activity are protective 25factors against asthma, whereas leisure television watching is a risk factor. Frequent leisure Television watching is 26 closely associated with an increased susceptibility to chronic obstructive pulmonary disease. Computer using during 27 leisure time and overall acceleration average in physical activity are inversely related to the risk of developing 28

- pulmonary arterial hypertension. Higher engagement in driving and vigorous physical activity are causally linked to a
   reduced risk of obstructive sleep apnea syndrome.
- Conclusion: In summary, our analysis confirms the causal relationships between physical activity, sedentary behavior, and chronic respiratory diseases, providing genetic evidence that supports lifestyle modifications to reduce susceptibility to these conditions.

# The associations between leisure sedentary behaviors, physical activity and chronic respiratory diseases: a Mendelian randomization study



#### 35 Keywords

36 Leisure sedentary behaviors, Physical activity, Chronic respiratory disease, Mendelian randomization

37

### 38 Introduction

Chronic respiratory diseases impose a substantial global health burden, characterized by high incidence and 39 mortality rates and incurring considerable socioeconomic(1-5). According to the World Health Organization, as of 40 2019, asthma affected 262 million people globally, whereas chronic obstructive pulmonary disease (COPD) afflicted 41 over 200 million(6). The prevalence of bronchiectasis is also increasing worldwide(4, 7-10). Furthermore, idiopathic 42 pulmonary fibrosis (IPF) is a chronic, progressive disease characterized by scarring and stiffening of lung tissue, 43 ultimately leading to a permanent decline in pulmonary function(11). Each year, there are approximately 40,000 new 44 IPF diagnoses across Europe(12). Moreover, nearly one billion people worldwide are impacted by obstructive sleep 45 apnea syndrome (OSAS)(13), with prevalence rates of 24% in men and 9% in women aged 30–60(14, 15). Pulmonary 46 arterial hypertension (PAH), meanwhile, exhibits a global prevalence of approximately 1%, escalating to 10% among 47 those aged 65 and above(16). 48

49	Despite significant advancements in management and diagnosis (17-19), standard treatments for chronic
50	respiratory diseases still remain insufficiently effective or have multiple adverse drug reactions for a substantial
51	segment of patients, markedly affecting their quality of life(20). Consequently, it is crucial to identify modifiable risk
52	factors and explore potential therapeutic strategies to mitigate disease progression and prevent onset, with physical
53	activity (PA) and leisure sedentary behaviors (LSB) are one of these key factors.
54	Rehabilitation training, recognized as a vital component of treatment in the international guidelines for COPD,
55	has been acknowledged for its beneficial. For instance, a minimum of 26 minutes per week of moderate to vigorous
56	physical activity (MVPA) has been proposed as an attainable and beneficial objective for patients with ILD (21). In a
57	2013 randomized trial, Carson et al. found that physical training significantly improved fitness in individuals aged
58	eight and older with asthma(22). However, another randomized controlled trial in adults with severe asthma produced
59	incongruent results, indicating that MVPA and MVPA bouts lasting > 10 minutes were associated with a deterioration
60	in health-related quality of life (23). Among Individuals with bronchiectasis, reductions in PA and an increase in LSB
61	over one year were linked to heightened frequencies of acute exacerbations(24). Collectively, these studies highlight

the complex interplay between PA and chronic respiratory diseases, underscoring a critical need for more definitive
 research to elucidate this relationship.

This study aims to ascertain the impact of PA and LSB on chronic respiratory diseases, which will aid in 64 developing targeted and feasible strategies to reduce the risk of these conditions. While previous observational studies 65 have employed various statistical techniques to control for potential confounders(25, 26), these methods remain 66 susceptible to residual confounding and reverse causation, posing challenges in identifying replicable causes of 67 chronic respiratory diseases(27). In contrast, Mendelian Randomization (MR) leverages single nucleotide 68 polymorphisms (SNPs) as instrumental variables (IVs), providing a more robust framework for examining the causal 69 effects of specific exposures on outcomes(28, 29). Due to the random assortment during meiosis and the fixed 70 allocation of genetic variants at conception, MR inherently minimizes the risks of reverse causation and confounding 71 variables that are difficult to address in traditional observational analyses. This approach not only strengthens the 72 evidence for a causal relationship between PA, LSB and chronic respiratory disease but also offers a novel way to 73 disentangle correlation from true causation in epidemiological research. 74

7

75	This study utilizes SNPs related to PA and LSB, selected from genome-wide association studies (GWAS)
76	conducted by prominent international consortiums(30, 31). A two-sample MR design was implemented to explore the
77	influence of PA and LSB on the susceptibility of six prevalent chronic respiratory diseases: asthma, bronchiectasis,
78	COPD, IPF, PAH, OSAS. In contrast to prior research(32-34), which predominantly focused on a single respiratory
79	disease, our study provides a more comprehensive evaluation by encompassing multiple chronic respiratory
80	conditions that have not been thoroughly addressed in the literature. Furthermore, the outcome variables in this study
81	are drawn from meta-analysis GWAS summary statistics or the latest database, affording a larger sample size and
82	thereby enhancing the robustness and generalizability of our findings.
83	Overall, this paper employs a two-sample MR analysis to establish the genetic causal relationship between PA,
84	LSB and chronic respiratory diseases. The findings provide valuable insights for the development of effective
85	preventive intervention strategies on chronic respiratory diseases.
86	

# 87 Materials and methods

88 Study design

MR analysis rests on three essential assumptions to ensure its validity as an instrumental variable analysis method: 89 (1) the relevance assumption necessitates a robust association between the genetic variants and the targeted exposure; 90 (2) the independence assumption requires that the genetic variants are not correlated with any confounders of the 91 exposure-outcome relationship, ensuring that the observed associations are not confounded by external variables; (3) 92 the exclusion-restriction assumption stipulates that the genetic instruments affect the outcome solely through the 93 exposure, without any direct pathways influencing the outcome outside of the exposure. This selection process ensures 94 the reliability and validity of the MR analysis in deducing causal relationships 95 Fig 1 illustrates the framework of a two-sample MR analysis, in which genetic variants related to LSB and PA are 96 employed as IVs. LSB are categorized into three groups-television, computer and driving-while PA is grouped into 97 five categories: self-reported vigorous physical activity (VPA), self-reported MVPA, self-reported strenuous sports or 98 other exercises (SSOE), accelerometer-measured overall acceleration average activity, and accelerometer-assessed 99 fraction of time with accelerations exceeding 425 milli-gravities (mg). The main objective of study is to elucidate the 100 causal relationships between LSB, PA, and chronic respiratory diseases (asthma, bronchiectasis, COPD, IPF, PAH, 101 OSAS). 102

#### 103

#### 104 Data source of exposures: LSB and PA

Genetic instruments associated with LSB were identified from the GWAS that included 408,815 participants of 105 European ancestry from the UK Biobank(31). At the initial assessment, 45.7% of the participants were male, with an 106 average age of 57.4 years (standard deviation [SD] = 8.0). Sedentary time was measured through self-reported daily 107 hours engaged in three activities: watching television, using a computer for leisure (excluding work-related use), and 108 driving. On average, participants reported 2.8 hours for watching television (SD 1.5), 1.0 hour for leisure computer use 109 (SD 1.2), and 0.9 hour for driving per day (SD 1.0). A mixed linear model was employed to adjust for population 110 structure and cryptic relatedness, with adjustments for age, sex, population stratification and genotyping array. Only 111 genetic loci meeting the genome-wide significance threshold of P < 1E-8 were retained for use in this study. The 112 summary data are publicly accessible at https://www.ebi.ac.uk/gwas/publications/32317632. 113 Sourced from the UK Biobank, we utilized the largest currently available GWAS on PA, drawing exclusively on 114 participants of white European ethnicity (30). Both self-reported and accelerometer-based measures were used to 115

116 classify and assess PA levels. Self-report PA was categorized into MVPA, VPA, and SSOE. A touchscreen

questionnaire captured self-reported PA data, quantifying the frequency and intensity of moderate PA (MPA) and VPA. 117 Participants who chose "prefer not to answer" or "do not know", reported an inability to walk, or exceed 16 hours of 118 MPA or VPA were excluded. To quantify MVPA, the total minutes of total minutes of MPA and VPA were multiplied 119 by four and eight, respectively, and then summed to reflect their respective metabolic equivalents. 377,234 participants 120 were included in the MVPA analysis. For VPA, participants were categorized into those with no VPA (0 days/week) 121 122 versus those engaging in vigorous activity on three or more days per week ( $\geq 25$  minutes each session). Individuals not fitting these categories were excluded, leading to the inclusion of 98,060 cases and 162,995 controls in the VPA analysis. 123 The SSOE category was determined based on self-reported frequencies and duration of "strenuous exercise" and "other 124 exercises" over the past four weeks. Participants performing  $\geq 2-3$  days/weeks of these activities, each session lasting 12515-30 minutes, were considered into the SSOE cases (N = 124,842), whereas those reporting no such activities in the 126 past four weeks served as controls (N = 225,650). 127

For the accelerometer-based assessment, participants wore Axivity AX3 wrist-worn devices for up to seven days, enabling the collection of overall acceleration average and the fraction of accelerations > 425 mg—a threshold corresponding to approximately 6 METs f energy expenditure and representing VPA. Individuals with <3 days of valid recordings, missing data for each hour in the 24-hour cycle, or outliers exceeding four standard deviations above the mean were excluded, ultimately yielding 91,084 participants for overall acceleration average and 90,667 participants for fraction of accelerations > 425mg. Full summary data for this study can be accessed at <u>https://www.ebi.ac.uk/gwas/publications/29899525</u>, and additional details regarding the datasets are listed in Table A.1.

#### 136 Data source of outcomes: chronic respiratory diseases

In this research, we selected asthma, bronchiectasis, COPD, IPF, PAH and OSAS as the chronic respiratory diseases. 137 The latest published GWAS summary statistics meta-analysis, conducted by the Global Biobank Meta-analysis 138 139 Initiative (GBMI)(35), provided the pertinent data for asthma, COPD and IPF. This comprehensive analysis encompasses 95,554 cases of asthma and 833,538 controls from 14 databases, 54,606 cases of COPD and 887,000 140 controls from 12 datasets, and 6,257 cases of IPF and 947,616 controls from 9 biobanks. The complete statistics of 141 GBMI dataset are accessible at https://www.globalbiobankmeta.org/. 142 Additionally, genetic data was obtained from the 10th edition of the FinnGen Biobank for 2,372 cases of 143 bronchiectasis and 338,303 controls, 248 cases of PAH and 289,117 controls, and 46,975 cases of OSAS and 365,206 144

145 controls. This data can be freely accessed at <u>https://finngen.gitbook.io/documentation/data-download</u>. To avoid the 146 pleiotropic effects of cross-lineage cases(36), we exclusively used data from participants of European ancestry. The 147 further details regarding the datasets can be found in Table S1 in Supplementary File A.

148

#### 149 Selection of instrumental variables

150 Prior to MR analysis, a rigorous protocol must be followed to ensure the reliability and robustness of SNPs. First, SNPs are screened based on a genome-wide significance threshold of P < 5E-8, ensuring that SNPs significantly 151associated with the exposure. Second, to mitigate the influence of linkage disequilibrium (LD) clumping among IVs, 152SNPs are clumped using standard parameters (clumping window of 10,000 kb and LD r<sup>2</sup> cutoff of 0.001). Third, SNPs 153significantly associated with the outcomes (P < 5E-8) are eliminated. Fourth, harmonization processes are conducted 154 to exclude palindromic and incompatible SNPs. Fifth, the GWAS catalog database (https://www.ebi.ac.uk/gwas/home) 155is utilized to assess each SNP associated with potential confounding traits, and such SNPs are manually excluded, 156 followed by re-analysis to uphold the independence assumption. Details of potential confounding traits and excluded 157SNPs are documented in Tables A.2 and A.3, respectively. Sixth, the MR-Pleiotropy Residual Sum and Outlier (MR-158

PRESSO) test is applied to identify any horizontal pleiotropy and correct outliers that could bias MR results. Following the exclusion of outlier SNPs, MR analysis are re-evaluated to ensure robustness(37). Table A.4 lists the outlier SNPs identified. Lastly, the *F*-statistic is commonly employed to gauge the strength of IVs, with values below 10 indicating weak instrument bias. SNPs with F-statistics below this threshold are excluded.

163

#### 164 MR analysis and Sensitivity analysis

To determine the causal relationship between exposures and outcomes, five prevalent MR methods were mostly utilized: MR Egger, Weighted median, Inverse Variance Weighted (IVW), Simple mode, and Weighted mode. The Wald ratio method be employed when only one SNP is available. MR Egger can yield unbiased estimates when some genetic variants are invalid instruments but is sensitive to weak instruments, potentially resulting in estimation bias(38). The Weighted median method can provide unbiased causal effect estimates even with up to 50% invalid instruments, demonstrating considerable robustness(39). The IVW method integrates the Wald ratios of each SNP to obtain a composite causal estimate, and conducts a weighted linear regression of the associations among the IVs. Notably, the IVW approach is applicable even when only two SNPs are available. If the results from these methods diverge, the
IVW result is prioritized.

Moreover, sensitivity analyses were performed to ensure the authenticity and reliability of the findings. Horizontal 174 pleiotropy, where genetic variations directly influence an outcome through pathways independent of the expected 175exposure, was assessed using the MR Egger intercept. A lack of significant horizontal pleiotropy was inferred if the 176 intercept P-value exceeded 0.05. Heterogeneity was assessed using Cochran's Q statistic, applicable to both MR-Egger 177and MR-IVW methods. A P > 0.05 indicated no significant heterogeneity. When only two SNPs were available, the 178 MR-IVW method is exclusively used. 179 Additionally, funnel plots, scatter plots, and leave-one-out analyses were performed to assess the reliability of the 180 causal estimates. Funnel plots graphically depict the causal effect estimates of each SNP with its precision, offering a 181 visual assessment of potential asymmetry. Scatter plots illustrate strength and direction of the instruments variables 182 effect and examines the linearity of the causal effect. Leave-one-out analysis sequentially removes each SNP and 183

recalculates the IVW estimate to detects the influence of individual SNP on the overall causal estimate. Significant

185 changes in causal estimates after removing an SNP suggest its potential outlier status. A minimum of three SNPs is 186 required to conduct this analysis effectively.

187 All statistical and sensitivity analyses were conducted using the R software (version 4.2.2) TwoSampleMR package

188 (version 0.5.6), ensuring reproducibility and standardization of the analytical workflow.

189

- 190 **Results**
- 191 Overview

After implementing stringent quality control measures, we identified independent SNPs significantly associated with the exposures (P < 5E-08,  $r^2 < 0.001$ ). Tables A.5 and A.6 details the *F*-statistics for each SNP, which ranged from 66.004 to 288.378, indicating the low likelihood of weak instruments bias. The number of SNPs utilized for each phenotype and its corresponding outcome varied, ranging from 1 to 80, as detailed in Tables A.7 – 12. Given the binary outcomes employed in this study, MR estimates were presented as odds ratios (OR) with 95% confidence intervals (CI) to ensure statistical precision. Fig 2 depicts the eight statistically significant causal relationships (P < 0.05 in IVW), including the associations of leisure television watching, VPA, and SSOE with asthma; leisure television watching with COPD; leisure computer using and overall average acceleration with PAH; and driving and VPA with OSAS.

201

#### 202 MR estimates

Significant MR results from the IVW method (P < 0.05) are presented in Table 1. IVW method demonstrated that 203 leisure television watching was significantly associated with increased asthma risk (OR = 1.358; 95% CI: 1.128–1.635; 204 P = 0.001). Parallel analyses using weighted median (OR = 1.585; 95% CI: 1.274–1.972; P = 3.584E–05), simple mode 205 206 (OR = 1.724; 95% CI: 1.136-2.616; P = 0.018) and weighted mode (OR = 1.742; 95% CI: 1.154-2.631; P = 0.015)support this finding. Additionally, VPA (OR = 0.991; 95% CI: 0.986–0.996; P = 0.001) and SSOE (OR = 0.985; 95% 207 CI: 0.978-0.991; P = 1.317E-06) were identified as protective factors. Table A.7 presents the weighted median analysis, 208 which indicates a nominally significant protective influence for both VPA (OR = 0.991; 95% CI: 0.984-0.997; P = 209 0.006) and SSOE (OR = 0.986; 95% CI: 0.978–0.995; P = 0.002). Furthermore, the primary IVW analysis revealed a 210 detrimental effect of leisure television watching on COPD (OR = 1.718; 95% CI: 1.347-2.190; P = 1.282E-05), 211

212 corroborated by weighted median (OR = 1.805; 95% CI: 1.356-2.404; P = 5.228E-05) in Table A.8. Meanwhile, leisure computer using (OR = 0.017; 95% CI: 0.001-0.238; P = 0.003) and overall average acceleration (OR = 0.511; 95% CI: 213 0.270–0.967; P = 0.039) was found to have a protective effect on PAH in the IVW analysis, a trend of computer using 214 also reflected in Table A.9 under the Weighted Median (OR = 0.022; 95% CI: 0.001-0.730; P = 0.033). For OSAS, 215 both driving (OR = 0.385; 95% CI: 0.185–0.801; P =0.011) and VPA (OR = 0.987; 95% CI: 0.980–0.995; P =0.001) 216 show protective associations, with weight median analysis yielding a significant protective effect for VPA (OR = 0.986; 217 95% CI: 0.977–0.995; P =0.002), as detailed in Table A.10. However, no causal association was detected between LSB, 218 PA, IPF, or bronchiectasis using the IVW analysis (Tables A.11 and A.12). Figure 3 provides forest plots illustrating 219 the range of meaningful causal estimates. 220 221

#### 222 Sensitivity analyses

- 223 Sensitivity studies, the Cochran's *Q* test and the MR-Egger intercept test, were conducted to evaluate the
- robustness of the aforementioned conclusions. The MR-Egger intercept remained near zero (P > 0.05), suggesting

225	minimal risk of horizontal pleiotropy. Nevertheless, Cochran's $Q$ test indicated heterogeneity ( $Q_P$ val < 0.05) in
226	several associations, including leisure television watching with asthma ( $P = 0.008$ in IVW, $P = 0.007$ in MR Egger),
227	SSOE with asthma ( $P = 0.030$ for IVW), and leisure television watching with COPD ( $P = 4.587E-04$ for IVW;
228	P = 0.001 for MR Egger). Despite this heterogeneity, the validity of the MR estimates was not undermined, given the
229	strong strength of the IVs and the application of random-effect IVW model, both of which help mitigate
230	heterogeneity concerns. Additional sensitivity analyses further reinforced the robustness of findings, indicating that
231	the observed heterogeneity did not undermine the reliability or interpretability of analysis results. Detailed on
232	horizontal pleiotropy and heterogeneity, including their statistical tests, are presented in Tables S7-S12 of
233	Supplementary File A, offering a more comprehensive overview of these sensitivity assessments.
234	Scatter plots (Fig $B.1 - 6$ ) depicted the effect sizes of associations between LSB and chronic respiratory diseases,
235	as determined various by MR methods. Leave-one-out analysis (Fig B.7 - 12) showed the contribution of individual
236	SNPs to the overall causality, revealing that no single SNP substantially drove the significant results. To assess the
237	effect sizes of individual SNPs of LSB on chronic respiratory diseases, forest plots (Fig B.13 - 18) provide detailed
238	views of effect sizes, allowing a closer examination of how each instrument contributes to the overall association.

Moreover, funnel plots (Fig. B.19–B.24) under the IVW model appear symmetrical, suggesting minimal evidence of estimates violation and further reinforcing the reliability of these significant causal findings.

241

#### 242 **Discussion**

Chronic respiratory diseases remain a significant global health concern, and conflicting observational evidence has 243 complicated efforts to establish clear links between physical exercise and chronic respiratory illnesses(22, 23). This 244 study leverages large-scale international consortium GWAS on PA and LSB to propose viable strategies for the 245 prevention of chronic respiratory diseases. Specifically, we selected six common chronic respiratory diseases—namely 246 247 asthma, bronchiectasis, COPD, IFP, PAH, and OSAS-from GBMI and Finngen R10 datasets. Employing a twosample MR approach, we identified eight statistically significant causal relationships that highlight the potential impact 248 of lifestyle modifications. 249 PA and LSB appear to exert important but contrasting influences on asthma risk. Our research indicates that long-250

- term television viewers are more likely to develop asthma, whereas SSOE and VPA can reduce the risk. This aligns
- with previous findings that reduced PA levels heighten the likelihood of new-onset asthma among children and

253 adolescents (40), and that increased PA can reduce the incidence of asthma(41). Mechanistically, moderate increases in PA may offset obesity-related risk factors by alleviating airway compression and chronic inflammation(42). Potential 254 mediating pathways involve Th-1-mediated immune responses, alterations in adipokine levels, and the activation of 255 the pyrin domain-containing 3 (NLRP3) inflammasome (43-45). Although our results underscore the importance of 256 reducing television watching time and increasing energy-consuming activities like SSOE and VPA to alleviate obesity 257 and lower asthma risk, the precise molecular underpinnings of these associations remain incompletely defined, calling 258 for in-depth mechanistic research to elucidate the interplay between obesity, immune dysregulation, and lifestyle 259 interventions. 260

Leisure television watching, a prevalent sedentary behavior(46), emerged in this study as a potential contributor to increased COPD susceptibility. This aligns with the known association between sedentary behavior and COPD-related mortality(47), potentially mediated by diminished muscle mass and strength—including respiratory muscles such as the diaphragm and intercostals. Prolonged television watching may also coincide with unhealthy lifestyle habits, such as smoking and alcohol consumption(48, 49), and tends to be more prevalent among individuals with lower socioeconomic status(50), which can exacerbate exposures to indoor air pollution and occupational hazards. Nonetheless, establishing a definitive causal chain linking LSB and COPD requires further investigation, ideally
 through longitudinal designs with objective measures of sedentary time and extensive confounding control.

For PAH, our research indicates that overall average acceleration may reduce susceptibility to PAH, aligning with the research that exercise enhances right ventricular mass and attenuates pulmonary vascular resistance(51, 52). Intriguingly, our findings also indicate that prolonged leisure computer use may also appeared to exert a beneficial influence on PAH susceptibility, an observation that warrants caution in interpretation. Mechanistic plausibility may involve modifying vascular function and endothelial function (53), yet clear epidemiological evidence on this front is sparse. Further randomized controlled trials are crucial to clarify whether and how LSB might beneficially modulate cardiopulmonary physiology and the onset of PAH.

Our findings indicate that driving behaviors and VPA are inversely correlated with OSAS risk. Given the pivotal role of obesity in OSAS pathogenesis, sustained VPA may reduce fat accumulation in the pharyngeal area, lowering airway collapsibility during sleep (54, 55). Furthermore, inflammation are critical components of OSAS-related diseases(56). Regular training can enhance regulatory T cells levels and lowers pro-inflammatory cytokines, thereby reducing inflammation and potentially alleviating OSAS severity(57, 58). The protective link between driving and OSAS, however, is less straightforward. It may be partially attributable to genetic variants such as rs476554, suggesting that this genetic variant, linked to driving, may reduce OSAS risk through an unknown mechanism. Larger genomic datasets incorporating detailed phenotypic assessments are needed to parse these unexpected associations more conclusively.

285 Consistent with prior research (25, 26, 32-34), our study reaffirms that leisure television watching heightens the 286 risk of asthma and COPD, whereas VPA appears protective against OSAS. Beyond these confirmatory results, we offer 287 novel insights: SSOE and VPA were linked to reduced asthma risk, and overall average acceleration correlated inversely 288 with PAH. Surprisingly, leisure computer using and driving activities—traditionally considered more sedentary—also 289 displayed inverse associations with PAH and OSAS, respectively. Genetic variants associated with these behaviors may 290 partly explain the unexpected findings, but the small number of SNPs analyzed highlights the need for greater statistical 291 power and more nuanced phenotypic data.

Our investigation benefits from a two-sample MR analysis that substantially reduces residual confounding and reverse causality (27). We drew upon large-scale GWAS studies with ample statistical power, and employed pleiotropy and sensitivity analyses to stringently evaluated violations of MR assumptions. Restricting our sample to Europeanancestry participants also minimized bias due to population stratification. Additionally, the SNPs related to PA and
LSB identified in our study have an *F*-statistic greater than 66, indicating strong instrumental validity.

Several limitations merit consideration. First, self-reported and accelerometer-based measurements of PA and LSB 297 may not accurately represent the complexity of real-world activity patterns, raising concerns over reporting bias. Second, 298 the relatively small number of SNPs for certain PA and LSB may have affected the precision of our MR estimates, 299 especially concerning unexpected protective findings. Third, our reliance on aggregated data constrains the possibility 300 of performing age- or sex-stratified analyses, nor does it allow for a precise quantification of the benefits of PA for 301 different chronic respiratory diseases. Fourth, our dataset is confined to participants of European descent, limiting the 302 generalizability of these findings. Caution is therefore warranted when extrapolating our findings to other populations. 303 In summary, this two-sample MR study investigated the causal relationship between PA, LSB, and chronic 304 respiratory disorders from asthma and COPD to PAH and OSAS. However, MR estimates predominantly reflect the 305 impact of lifetime exposure to risk factors, and the clinical relevance of modifying these behaviors at discrete life stages 306 remains uncertain(59). Additional randomized controlled trials are imperative to validate whether targeted interventions 307 can effectively alter the trajectory of chronic respiratory diseases. By integrating mechanistic research, advanced 308

309 genomic tools, and diverse populations, future studies may clarify how best to translate these findings into meaningful
 310 clinical interventions for chronic respiratory disease prevention and care.

311

### 312 Conclusion

Utilizing existing GWAS databases to select robust genetic variants as IVs, this study employed a two-sample 313 Mendelian randomization approach to elucidate the causal relationships between LSB and PA, and chronic respiratory 314 diseases. Our results indicate a causal association between strenuous sports or other exercises and vigorous PA with 315 reduced asthma risk, whereas leisure Television watching correlates with an increased risk. Additionally, leisure 316 Television watching was positively correlated with the risk of developing COPD. Computer using during leisure time 317 and overall acceleration average was inversely related to susceptibility to PAH. Engaging in driving and VPA were 318 protective factors against OSAS. Our findings suggest new directions for understanding the impacts of PA and LSB 319 on chronic respiratory diseases. Future randomized controlled trials could benefit from focusing more on these aspects 320 to further validate and expand upon our results. 321

322

# 323 Figures

### 324 Figure 1. Study Overview.



325

Instrument variables, predominantly SNPs, associated with LSB and PA are chosen to estimate the causal effects on chronic respiratory diseases. The selected IVs are required to satisfy stringent criteria: they must exhibit robust associations with the exposure, be independent of confounders of the exposure and outcome, and exert their impact on the outcome exclusively through the exposure.

- 330 Abbreviations: COPD, Chronic Obstructive Pulmonary Disease; IPF, Idiopathic Pulmonary Fibrosis; PAH, Pulmonary
- 331 Arterial Hypertension; OSAS, Obstructive Sleep Apnea Syndrome; IVs, Instrument variables; SNPs, Single Nucleotide
- 332 Polymorphisms;
- 333
- **Figure 2. Causal effects of LSB, PA and chronic respiratory diseases.**



335

This figure illustrates the significant causal relationships, denoted by P < 0.05 of IVW, between LSB, PA, and chronic

337 respiratory diseases.

- 338 Abbreviations: VPA, Vigorous Physical Activity; MVPA, Moderate to Vigorous Physical Activity; SSOE, Strenuous
- 339 Sports or Other Exercises; COPD, Chronic Obstructive Pulmonary Disease; IPF, Idiopathic Pulmonary Fibrosis; PAH,
- Pulmonary Arterial Hypertension; OSAS, Obstructive Sleep Apnea Syndrome; IVW, Inverse Variance Weighted.
   341
- Figure 3. Forest plots illustrating the meaningful estimated causal effects of LSB, PA and chronic respiratory
   diseases.



Exposure	Outcome	Method	nSNP	Р	OR(95%CI)
Television	Asthma	Inverse variance weighted	22	0.001	1.358(1.128 to 1.635)
		Weighted median	22	3.584e-05	1.585(1.274 to 1.972)
		Simple mode	22	0.018	→ 1.724(1.136 to 2.616)
		Weighted mode	22	0.015	→ 1.742(1.154 to 2.631)
VPA	Asthma	Inverse variance weighted	4	0.001	0.991(0.986 to 0.996)
		Weighted median	4	0.006	0.991(0.984 to 0.997)
SSOE	Asthma	Inverse variance weighted	4	1.317e-06	0.985(0.978 to 0.991)
		Weighted median	4	0.002	0.986(0.978 to 0.995)
Television	COPD	Inverse variance weighted	29	1.282e-05	→ 1.718(1.347 to 2.190)
		Weighted median	29	5.228e-05	➡ 1.805(1.356 to 2.404)
Computer	PAH	Inverse variance weighted	21	0.003 🛏	0.017(0.001 to 0.238)
		Weighted median	21	0.033	0.022(0.001 to 0.730)
Average acceleration	PAH	Inverse variance weighted	2	0.039	0.511(0.270 to 0.967)
Driving	OSAS	Inverse variance weighted	2	0.011	0.385(0.185 to 0.801)
VPA	OSAS	Inverse variance weighted	5	0.001	0.987(0.980 to 0.995)
		Weighted median	5	0.002	0.986(0.977 to 0.995)

344

- <sup>345</sup> The MR estimates derived from the IVW, weighted median, simple mode and weighted mode.
- 346 Abbreviations:
- 347 VPA, Vigorous Physical Activity; MVPA, Moderate to Vigorous Physical Activity; SSOE, Strenuous Sports or Other
- 348 Exercises; COPD, Chronic Obstructive Pulmonary Disease; IPF, Idiopathic Pulmonary Fibrosis; PAH, Pulmonary
- 349 Arterial Hypertension; OSAS, Obstructive Sleep Apnea Syndrome; MR, Mendelian Randomization; SNP, Single
- 350 Nucleotide Polymorphism.

# 352 **Table**

# **Table 1. MR results regarding the causally impact of PA and LSB on chronic respiratory diseases.**

Exposure	Outcome	Method	SNPs	OR (95% CI)	Р
Television	Asthma	Inverse Variance Weighted	22	1.358 (1.128, 1.635)	0.001
VPA	Asthma	Inverse Variance Weighted	4	0.991 (0.986, 0.996)	0.001
SSOE	Asthma	Inverse Variance Weighted	4	0.985 (0.978, 0.991)	1.317E-06
Television	COPD	Inverse Variance Weighted	29	1.718 (1.347, 2.190)	1.282E-05
Computer	РАН	Inverse Variance Weighted	21	0.017 (0.001, 0.238)	0.003
Driving	OSAS	Inverse Variance Weighted	2	0.385 (0.185, 0.801)	0.011
VPA	OSAS	Inverse Variance Weighted	5	0.987 (0.980, 0.995)	0.001

354 Note: P < 0.05 represents the causal association.

Abbreviations: MR, Mendelian Randomization; SNPs, Single Nucleotide Polymorphisms; OR, Odds Ratio; CI,
 Confidence Interval; *P*, *P* Value; VPA, Vigorous Physical Activity; SSOE, Strenuous Sports or Other Exercises; COPD,
 Chronic Obstructive Pulmonary Disease; IPF, Idiopathic Pulmonary Fibrosis; PAH, Pulmonary Arterial Hypertension;
 OSAS, Obstructive Sleep Apnea Syndrome.

359

#### 360 Acknowledgements

361 The authors express their deep gratitude to Dr. Yord Vegte and his team for sharing the statistical summaries on

362 LSB, and to Dr. Yann Klimentidis and his team for their contributions on the GWAS statistical summaries of PA. We

also extend our thanks to the GBMI database for providing data related to asthma, COPD and IPF, and to the Finngen

database for data on bronchiectasis, PAH and OSAS. Additionally, our appreciation goes to the GWAS catalog project

365 (https://www.ebi.ac.uk/gwas/home) for making available summarized results pertinent to this paper.

366

#### 367 Formatting of funding sources

368 This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit 369 sectors.

370

#### **Data availability statement:**

372 All relevant data are contained within the manuscript and its supplementary information files.

373 The datasets supporting the findings of this study are publicly available at the following URLs: LSB

374 (https://www.ebi.ac.uk/gwas/publications/32317632); PA (https://www.ebi.ac.uk/gwas/publications/29899525);

asthma, COPD, and IPF from GBMI (<u>https://www.globalbiobankmeta.org/</u>); data on bronchiectasis, PAH, and OSAS

376 provided by Finngen R10 (<u>https://finngen.gitbook.io/documentation/data-download</u>);. The Mendelian Randomization

377 (MR) analysis code is available at <u>https://mrcieu.github.io/TwoSampleMR/articles/index.html</u>.

378

#### 379 **Competing interests**

380 The authors declare that they have no known competing financial interests or personal relationships that could 381 have appeared to influence the work reported in this paper.

#### 382

#### 383 Ethics statement

The GWAS data used in this article are anonymous and open access, available on the web, so it was not essential to obtain the ethical approval by the institutional review board of Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine.

387

#### 388 Author contributions

Yuxin Zou (YZ) conceptualized and designed the study, performed the data analysis, and drafted the manuscript.
Manyi Pan (MP) contributed to assist with data analysis, and contribute to the final drafting of the manuscript. Huaqi
Guo (HG) was involved in the study design, supervised the study, and provided critical revisions to the manuscript. All
authors critically reviewed and revised the manuscript and agreed on the published version of the manuscript.

# 394 Declaration of Generative AI and AI-assisted technologies in the writing process

395 During the preparation of this work, we utilized the ChatGPT of OpenAI in order to improve readability and language.

- After using this tool, we reviewed and edited the content as needed and take full responsibility for the content of the 396
- 397 publication.
- 398

#### References 399

- 400 [1] Asher MI. Garcia-Marcos L, Pearce NE, Strachan DP. Trends in worldwide asthma prevalence. Eur Respir J 2020; 56:2002094.
- 401 [2] Fietze I, Laharnar N, Obst A et al. Prevalence and association analysis of obstructive sleep apnea with gender and age differences
- 402 - Results of SHIP-Trend. J Sleep Res 2019: 28:e12770.
- 403 [3] Podolanczuk AJ, Thomson CC, Remy-Jardin M et al. Idiopathic pulmonary fibrosis: state of the art for 2023. Eur Respir J 2023; 404 61:2200957.
- [4] Quint JK, Millett ER, Joshi M et al. Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 405 406 2013: a population-based cohort study. Eur Respir J 2016; 47:186-193.
- 407 [5] Wang C, Xu J, Yang L et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary 408 Health [CPH] study): a national cross-sectional study. Lancet 2018; 391:1706-1717.
- 409 [6] Vos T, Lim SS, Abbafati C et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a 410
- systematic analysis for the Global Burden of Disease Study 2019. The lancet 2020; 396:1204-1222.
- 411 [7] Ringshausen FC, de Roux A, Diel R, Hohmann D, Welte T, Rademacher J. Bronchiectasis in Germany: a population-based estimation of
- 412 disease prevalence. Eur Respir J 2015; 46:1805-1807.
- 413 [8] Ringshausen FC, de Roux A, Pletz MW, Hamalainen N, Welte T, Rademacher J. Bronchiectasis-associated hospitalizations in Germany,
- 414 2005-2011: a population-based study of disease burden and trends. PLoS One 2013; 8:e71109.
- 415 [9] Sanchez-Munoz G, Lopez de Andres A, Jimenez-Garcia R et al. Time Trends in Hospital Admissions for Bronchiectasis: Analysis of
- 416 the Spanish National Hospital Discharge Data (2004 to 2013). PLoS One 2016; 11:e0162282.

- 417 [10] Seitz AE, Olivier KN, Adjemian J, Holland SM, Prevots DR. Trends in bronchiectasis among medicare beneficiaries in the United
   418 States, 2000 to 2007. Chest 2012; 142:432-439.
- [11] Raghu G, Collard HR, Egan JJ et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based
   guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183:788-824.
- 421 [12] Navaratnam V, Fleming KM, West J et al. The rising incidence of idiopathic pulmonary fibrosis in the U.K. Thorax 2011; 66:462–
   422 467.
- [13] Benjafield AV, Ayas NT, Eastwood PR et al. Estimation of the global prevalence and burden of obstructive sleep apnoea: a
   literature-based analysis. Lancet Respir Med 2019; 7:687-698.
- 425 [14] Salzano G, Maglitto F, Bisogno A et al. Obstructive sleep apnoea/hypopnoea syndrome: relationship with obesity and management in 426 obese patients. Acta Otorhinolarvngol Ital 2021: 41:120-130.
- 427 [15] Senaratna CV, Perret JL, Lodge CJ et al. Prevalence of obstructive sleep apnea in the general population: A systematic review.
  428 Sleep Med Rev 2017; 34:70-81.
- 429 [16] Hoeper MM, Humbert M, Souza R et al. A global view of pulmonary hypertension. Lancet Respir Med 2016; 4:306-322.
- 430 [17] Yue M, Tao S, Gaietto K, Chen W. Omics approaches in asthma research: Challenges and opportunities. Chinese Medical Journal
- 431 Pulmonary and Critical Care Medicine 2024; 2:1-9.
- 432 [18] Zhang J, Chen F, Wang Y, Chen Y. Early detection and prediction of acute exacerbation of chronic obstructive pulmonary disease.
- 433 Chinese Medical Journal Pulmonary and Critical Care Medicine 2023; 1:102-107.
- [19] Zhang L, Jia X, Zhang Z, Yu T, Geng Z, Yuan L. Mining Potential Molecular Markers and Therapeutic Targets of COPD Based on
   Transcriptome-Sequencing and Gene-Expression Chip. Arch Med Sci 2024.
- 436 [20] Jasinska-Stroschein M, Stawarczyk K, Stepien A, Orszulak-Michalak D. Comparative tolerability of targeted therapies in pulmonary
- 437 hypertension. Arch Med Sci 2024; 20:167-188.
- 438 [21] Hur SA, Guler SA, Khalil N et al. Minimal Important Difference for Physical Activity and Validity of the International Physical
   439 Activity Questionnaire in Interstitial Lung Disease. Ann Am Thorac Soc 2019; 16:107-115.
- [22] Carson KV, Chandratilleke MG, Picot J, Brinn MP, Esterman AJ, Smith BJ. Physical training for asthma. Cochrane Database Syst Rev
   2013:CD001116.
- 442 [23] Neale J, Orme MW, Majd S et al. A comparison of daily physical activity profiles between adults with severe asthma and healthy 443 controls. Eur Respir J 2020; 56:1902219.

- 444 [24] Alcaraz-Serrano V, Arbillaga-Etxarri A, Oscanoa P et al. Exacerbations and Changes in Physical Activity and Sedentary Behaviour
- 445 in Patients with Bronchiectasis after 1 Year. J Clin Med 2021; 10:1190.
- 446 [25] Liang H, Jing D, Zhu Y et al. Association of genetic risk and lifestyle with incident adult-onset asthma in the UK Biobank cohort.
- 447 ERJ Open Res 2023; 9.
- 448 [26] Lei Y, Zou K, Xin J et al. Sedentary behavior is associated with chronic obstructive pulmonary disease: A generalized propensity
- 449 score-weighted analysis. Medicine (Baltimore) 2021; 100:e25336.
- 450 [27] Boyko EJ. Observational research--opportunities and limitations. J Diabetes Complications 2013; 27:642-648.
- 451 [28] Richmond RC, Davey Smith G. Mendelian Randomization: Concepts and Scope. Cold Spring Harb Perspect Med 2022; 12:a040501.
- 452 [29] Smith GD, Ebrahim S. 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants
- 453 of disease? Int J Epidemiol 2003; 32:1-22.
- 454 [30] Klimentidis YC, Raichlen DA, Bea J et al. Genome-wide association study of habitual physical activity in over 377,000 UK Biobank
- 455 participants identifies multiple variants including CADM2 and APOE. Int J Obes (Lond) 2018; 42:1161-1176.
- [31] van de Vegte YJ, Said MA, Rienstra M, van der Harst P, Verweij N. Genome-wide association studies and Mendelian randomization
   analyses for leisure sedentary behaviours. Nat Commun 2020; 11:1770.
- [32] Xiao L, Li W, Li F et al. Assessing the causal role of physical activity and leisure sedentary behaviours with chronic obstructive
   pulmonary disease: a Mendelian randomisation study. BMJ Open Respir Res 2024; 11:e001879.
- 460 [33] Gao Y, Li C, Li J, Li L. Causal relationships of physical activity and leisure sedentary behaviors with COPD: A Mendelian 461 randomization study. Arch Gerontol Geriatr 2024; 121:105364.
- 462 [34] Tian H, Wang A, Wu H, Zhou C, Zhang Z, Wang J. The causality between leisure sedentary behaviors, physical activity and obstructive
   463 sleep apnea: a bidirectional Mendelian randomization study. Front Public Health 2024; 12:1425060.
- 464 [35] Zhou W, Kanai M, Wu KH et al. Global Biobank Meta-analysis Initiative: Powering genetic discovery across human disease. Cell
   465 Genom 2022; 2:100192.
- [36] Burgess S, Davey Smith G, Davies NM et al. Guidelines for performing Mendelian randomization investigations: update for summer
   2023. Wellcome Open Res 2019; 4:186.
- 468 [37] Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian 469 randomization between complex traits and diseases. Nat Genet 2018; 50:693-698.
- 470 [38] Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through

- 471 Egger regression. Int J Epidemiol 2015; 44:512-525.
- 472 [39] Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in Mendelian Randomization with Some Invalid Instruments
- 473 Using a Weighted Median Estimator. Genet Epidemiol 2016; 40:304-314.
- 474 [40] Lochte L, Nielsen KG, Petersen PE, Platts-Mills TA. Childhood asthma and physical activity: a systematic review with meta-analysis
- 475 and Graphic Appraisal Tool for Epidemiology assessment. BMC Pediatr 2016; 16:50.
- 476 [41] Eijkemans M, Mommers M, Draaisma JM, Thijs C, Prins MH. Physical activity and asthma: a systematic review and meta-analysis. PLoS
   477 One 2012; 7:e50775.
- 478 [42] Salome CM, King GG, Berend N. Physiology of obesity and effects on lung function. J Appl Physiol (1985) 2010; 108:206-211.
- 479 [43] Muc M, Mota-Pinto A, Padez C. Association between obesity and asthma epidemiology, pathophysiology and clinical profile. Nutr
- 480 Res Rev 2016; 29:194-201.
- 481 [44] Umetsu DT. Mechanisms by which obesity impacts upon asthma. Thorax 2017; 72:174-177.
- 482 [45] Baffi CW, Winnica DE, Holguin F. Asthma and obesity: mechanisms and clinical implications. Asthma Res Pract 2015; 1:1.
- [46] Clark BK, Healy GN, Winkler EA et al. Relationship of television time with accelerometer-derived sedentary time: NHANES. Med Sci
   Sports Exerc 2011: 43:822-828.
- [47] O'Donnell DE, Revill SM, Webb KA. Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am J
   Respir Crit Care Med 2001; 164:770-777.
- [48] Gidwani PP, Sobol A, DeJong W, Perrin JM, Gortmaker SL. Television viewing and initiation of smoking among youth. Pediatrics
  2002; 110:505-508.
- [49] Gabrielli J, Corcoran E, Genis S, McClure AC, Tanski SE. Exposure to Television Alcohol Brand Appearances as Predictor of
   Adolescent Brand Affiliation and Drinking Behaviors. J Youth Adolesc 2022; 51:100-113.
- [50] Mesquita EDL, Tebar WR, Correia DCQ et al. Physical activity and sedentary behaviour of adolescents and their parents: a specific
   analysis by sex and socioeconomic status. Arch Public Health 2023; 81:189.
- 493 [51] Aaron CP, Tandri H, Barr RG et al. Physical activity and right ventricular structure and function. The MESA-Right Ventricle Study.
- 494 Am J Respir Crit Care Med 2011; 183:396-404.
- 495 [52] Ehlken N, Lichtblau M, Klose H et al. Exercise training improves peak oxygen consumption and haemodynamics in patients with
- 496 severe pulmonary arterial hypertension and inoperable chronic thrombo-embolic pulmonary hypertension: a prospective, randomized, 497 controlled trial. Eur Heart J 2016; 37:35-44.

- 498 [53] Maasakkers CM, Melis RJF, Kessels RPC et al. The short-term effects of sedentary behaviour on cerebral hemodynamics and cognitive
- 499 performance in older adults: a cross-over design on the potential impact of mental and/or physical activity. Alzheimers Res Ther 2020;
- 500 12:76.
- 501 [54] Young T, Skatrud J, Peppard PE. Risk factors for obstructive sleep apnea in adults. JAMA 2004; 291:2013-2016.
- 502 [55] Mayer P, Pepin JL, Bettega G et al. Relationship between body mass index, age and upper airway measurements in snorers and sleep
- 503 apnoea patients. Eur Respir J 1996; 9:1801-1809.
- [56] Lv R, Liu X, Zhang Y et al. Pathophysiological mechanisms and therapeutic approaches in obstructive sleep apnea syndrome. Signal
   Transduct Target Ther 2023; 8:218.
- 506 [57] Langston PK, Sun Y, Ryback BA et al. Regulatory T cells shield muscle mitochondria from interferon-gamma-mediated damage to 507 promote the beneficial effects of exercise. Sci Immunol 2023; 8:eadi5377.
- 508 [58] Gonzalo-Encabo P, Maldonado G, Valades D, Ferragut C, Perez-Lopez A. The Role of Exercise Training on Low-Grade Systemic 509 Inflammation in Adults with Overweight and Obesity: A Systematic Review. Int J Environ Res Public Health 2021; 18:13258.
- 510 [59] Burgess S, Swanson SA, Labrecque JA. Are Mendelian randomization investigations immune from bias due to reverse causation? Eur J 511 Epidemiol 2021: 36:253-257.
- 512

#### 513 **Supporting information**

- 514 Supplementary File A.
- 515 Supplementary File B.

# The associations between leisure sedentary behaviors, physical activity and chronic respiratory diseases: a Mendelian randomization study



#### 1 Table 1. MR results regarding the causally impact of physical activity and sedentary leisure behaviors on chronic

#### 2 respiratory diseases.

Exposure	Outcome	Method	SNPs	OR (95% CI)	Р
Television	Asthma	Inverse Variance Weighted	22	1.358 (1.128, 1.635)	0.001
VPA	Asthma	Inverse Variance Weighted	4	0.991 (0.986, 0.996)	0.001
SSOE	Asthma	Inverse Variance Weighted	4	0.985 (0.978, 0.991)	1.317E-06
Television	COPD	Inverse Variance Weighted	29	1.718 (1.347, 2.190)	1.282E-05
Computer	РАН	Inverse Variance Weighted	21	0.017 (0.001, 0.238)	0.003
Driving	OSAS	Inverse Variance Weighted	2	0.385 (0.185, 0.801)	0.011
VPA	OSAS	Inverse Variance Weighted	5	0.987 (0.980, 0.995)	0.001

3 Note: P < 0.05 represents the causal association.

- 4 Abbreviations: MR, Mendelian Randomization; SNPs, Single Nucleotide Polymorphisms; OR, Odds Ratio; CI,
- 5 Confidence Interval; P, P Value; VPA, Vigorous Physical Activity; SSOE, Strenuous Sports or Other Exercises; COPD,

- 6 Chronic Obstructive Pulmonary Disease; IPF, Idiopathic Pulmonary Fibrosis; PAH, Pulmonary Arterial Hypertension;
- 7 OSAS, Obstructive Sleep Apnea Syndrome.





Felevision         Asthma         Inverse variance weighted         22         0.001	Fielwison         Asthma         Inverse variance weighted         22         0.001         →→→→→→→→→→→→→→→→→→→→→→→→→→→→→→→→→→→→	elevision /PA SOE elevision computer vverage acceleration rriving /PA	Asthma Asthma Asthma COPD PAH OSAS OSAS	Inverse variance weighted Weighted median Simple mode Weighted mode Inverse variance weighted Weighted median Inverse variance weighted Weighted median Inverse variance weighted Weighted median Inverse variance weighted Inverse variance weighted Inverse variance weighted Inverse variance weighted Weighted median	22 22 22 4 4 4 29 29 21 21 21 2 2 5 5	0.001 3.584e-05 0.018 0.015 0.001 0.006 1.317e-06 0.002 1.282e-05 5.228e-05 0.003 0.033 0.039 0.011	1.358(1.128 to 1.635)         1.585(1.274 to 1.972)         1.724(1.136 to 2.616)         1.742(1.154 to 2.631)         0.991(0.986 to 0.996)         0.991(0.984 to 0.997)         0.985(0.978 to 0.991)         0.986(0.978 to 0.995)         1.718(1.347 to 2.190)         1.805(1.356 to 2.404)         0.017(0.001 to 0.238)         0.022(0.001 to 0.730)         0.511(0.270 to 0.967)
Weighted mode         22         3.684-05         Image: 1.784(1.138 to 2.816)           Weighted mode         22         0.015         Image: 1.724(1.138 to 2.816)           //PA         Astma         Inverse variance weighted         4         0.001         0.991(0.984 to 0.997)           SSDE         Astma         Inverse variance weighted         4         1.317e-06         0.986(0.978 to 0.997)           SSDE         Astma         Inverse variance weighted         29         1.282e-05         Image: 1.867(1.34 to 2.180)           SSDE         Astma         Inverse variance weighted         21         0.002         0.986(0.978 to 0.997)           SSDE         PAH         Inverse variance weighted         21         0.003         Image: 0.017(0.001 to 0.288)           Weighted median         21         0.039         Image: 0.017(0.001 to 0.288)         0.022(0.003,097)         Image: 0.028(0.017,001 to 0.987)           Yring         OSAS         Inverse variance weighted         2         0.011         Image: 0.028(0.019,001,098)         Image: 0.028(0.019,00,019,01,00,019)           Yring         OSAS         Inverse variance weighted         5         0.001         0.987(0.989,00,098)           Yring         OSAS         Inverse variance weighted         5         0.001	Weighted median         22         3.584-05	/PA SOE 'elevision computer werage acceleration Driving /PA	Asthma Asthma COPD PAH OSAS OSAS	Weighted median Simple mode Weighted mode Inverse variance weighted Weighted median Inverse variance weighted Weighted median Inverse variance weighted Weighted median Inverse variance weighted Inverse variance weighted Inverse variance weighted Inverse variance weighted Weighted median	22 22 4 4 29 29 21 21 21 2 2 5 5	3.584e-05 0.018 0.015 0.006 1.317e-06 0.002 1.282e-05 5.228e-05 0.003 0.033 0.039 0.011 0.001 0.001 0.001 0.003 0.003 0.003 0.001 0.003 0.005 0.005	Image: 1.585(1.274 to 1.972)         Image: 1.724(1.136 to 2.616)         Image: 1.724(1.136 to 2.631)         0.991(0.986 to 0.996)         0.991(0.986 to 0.996)         0.991(0.984 to 0.997)         0.985(0.978 to 0.991)         0.986(0.978 to 0.995)         Image: 1.718(1.347 to 2.190)         Image: 1.805(1.356 to 2.404)         0.017(0.001 to 0.238)         0.022(0.001 to 0.730)         0.511(0.270 to 0.967)
Simple mode         22         0.018         Image: 1.724(1.136 to 2.816)           VPA         Asthma         Inverse variance weighted         4         0.001         0.991(0.986 to 0.996)           SSDE         Asthma         Inverse variance weighted         4         0.002         0.985(0.978 to 0.996)           SSDE         Asthma         Inverse variance weighted         4         0.002         0.985(0.978 to 0.996)           SSDE         Asthma         Inverse variance weighted         2         0.282e-05         Image: 1.78(1.136 to 2.216)           SSDE         Asthma         Inverse variance weighted         2         0.033         Image: 1.78(1.136 to 2.816)           Signey mode         COPD         Inverse variance weighted         2         0.034         Image: 0.987(0.980 to 0.987)           Sample mode         2         0.033         Image: 0.511(0.2780 to 0.987)         Image: 0.511(0.2780 to 0.987)           Weighted median         15         0.001         0.987(0.980 to 0.985)         Image: 0.986(0.977 to 0.985)           P/PA         OSAS         Inverse variance weighted         2         0.001         0.986(0.977 to 0.985)           Image: 0.511(0.510 to 0.511(0.510 to 0.987)         Image: 0.511(0.510 to 0.987)         Image: 0.511(0.510 to 0.987)           Im	Simple mode         22         0.018	/PA SSOE 'elevision computer werage acceleration Driving /PA	Asthma Asthma COPD PAH OSAS OSAS	Simple mode Weighted mode Inverse variance weighted Weighted median Inverse variance weighted Weighted median Inverse variance weighted Weighted median Inverse variance weighted Inverse variance weighted Inverse variance weighted Weighted median	22 22 4 4 29 29 21 21 21 2 2 5 5 5	0.018 0.015 0.001 0.006 1.317e-06 0.002 1.282e-05 5.228e-05 0.003 0.033 0.033 0.039 0.011	Image: 1.724(1.136 to 2.616)         Image: 1.742(1.154 to 2.631)         0.991(0.986 to 0.996)         0.991(0.986 to 0.997)         0.995(0.978 to 0.991)         0.986(0.978 to 0.995)         Image: 1.718(1.347 to 2.190)         Image: 1.805(1.356 to 2.404)         0.017(0.001 to 0.238)         0.022(0.001 to 0.730)         0.511(0.270 to 0.967)
Verighted mode         22         0.015         Impact = 1,742(1,154 to 2.631)           JPA         Astima         Inverse variance weighted         4         0.001         0.991(0.984 to 0.997)           JSOE         Astima         Inverse variance weighted         4         1.317-06         0.985(0.978 to 0.991)           JSOE         Astima         Inverse variance weighted         29         1.282e-05         Impact = 1,778(1,1347 to 2.190)           Computer         PAH         Inverse variance weighted         21         0.003         0.021(0.001 to 0.238)           Verighted median         29         5.228e-05         Impact = 1,778(1,1347 to 2.190)         0.017(0.001 to 0.238)           Verighted median         21         0.033         0.022(0.001 to 0.730)         0.021(0.001 to 0.730)           Verighted median         5         0.001         0.039(0.0907)         0.389(0.0977 to 0.995)           Vring         OSAS         Inverse variance weighted         2         0.011         0.389(0.977 to 0.995)           Verighted median         5         0.002         0.986(0.977 to 0.995)         0           Verighted median         5         0.002         0.986(0.977 to 0.995)         0	Weighted mode         22         0.015         Image and the total and the weighted in the total and total and the total	/PA SSOE 'elevision computer verage acceleration Driving /PA	Asthma Asthma COPD PAH OSAS OSAS	Weighted mode Inverse variance weighted Weighted median Inverse variance weighted Weighted median Inverse variance weighted Weighted median Inverse variance weighted Inverse variance weighted Inverse variance weighted Weighted median	22 4 4 29 29 21 21 2 2 2 2 5 5	0.015 0.001 0.006 1.317e-06 0.002 1.282e-05 5.228e-05 0.003 0.033 0.033 0.039 0.011	↓       1.742(1.154 to 2.631)         0.991(0.986 to 0.996)         0.991(0.984 to 0.997)         0.985(0.978 to 0.991)         0.986(0.978 to 0.995)         ↓         1.718(1.347 to 2.190)         ↓         1.805(1.356 to 2.404)         0.017(0.001 to 0.238)         0.022(0.001 to 0.730)         0.511(0.270 to 0.967)
/PA         Asthma         Inverse variance weighted         4         0.001         0.991(0.986 to 0.997)           SOE         Asthma         Inverse variance weighted         4         0.006         0.991(0.986 to 0.997)           Iso         Asthma         Inverse variance weighted         4         0.002         0.988(0.978 to 0.997)           Iso         COPD         Inverse variance weighted         2         0.098(0.978 to 0.997)           Somutier         PAH         Inverse variance weighted         2         0.093           Weighted median         21         0.033         0.017(0.001 to 0.238)           Weighted median         21         0.033         0.022(0.001 to 0.730)           Vienge variance weighted         2         0.033         0.011 (0.278 to 0.967)           Vienge variance weighted         2         0.001         0.383(0.185 to 0.801)           Vienge variance weighted         5         0.001         0.383(0.185 to 0.801)           (PA         OSAS         Inverse variance weighted         5         0.001         0.987(0.900 to 0.955)           Weighted median         5         0.002         0.986(0.977 to 0.995)         0.986(0.977 to 0.995)	/PA         Astma         Inverse variance weighted Weighted median         4         0.006         0.991(0.984 to 0.997)           SOE         Astma         Inverse variance weighted Weighted median         4         0.002         0.986(0.978 to 0.997)           Iselevision         COPD         Inverse variance weighted Weighted median         2         0.288         0.989(0.978 to 0.997)           Computer         PAH         Inverse variance weighted 2         0.003	/PA SSOE `elevision computer vverage acceleration Driving /PA	Asthma Asthma COPD PAH OSAS OSAS	Inverse variance weighted Weighted median Inverse variance weighted Weighted median Inverse variance weighted Weighted median Inverse variance weighted Inverse variance weighted Inverse variance weighted Inverse variance weighted Weighted median	4 4 29 29 21 21 2 2 2 2 5 5	0.001 0.006 1.317e-06 0.002 1.282e-05 5.228e-05 0.003 0.033 0.033 0.039 0.011	0.991 (0.986 to 0.996) 0.991 (0.984 to 0.997) 0.985 (0.978 to 0.991) 0.986 (0.978 to 0.995) 1.718 (1.347 to 2.190) 1.805 (1.356 to 2.404) 0.017 (0.001 to 0.238) 0.022 (0.001 to 0.730) 0.511 (0.270 to 0.967)
Weighted median         4         0.006         0.991(0.984 to 0.997)           SSOE         Asthma         Inverse variance weighted         2         1.317e-06         0.0980(0.978 to 0.995)           Felevision         COPD         Inverse variance weighted         2         1.282e-05         ++++++++++++++++++++++++++++++++++++	SSOE Asthma Inverse variance weighted 4 0.006 0.991(0.994 to 0.997) SSOE Asthma Inverse variance weighted 2 1.317e-06 0.988(0.978 to 0.995) Ielevision COPD Inverse variance weighted 2 1.282e-05 0.001 10.738 Computer PAH Inverse variance weighted 2 10.003 0.002 0.017(0.001 to 0.288) Weighted median 2 10.033 0.002 0.017(0.001 to 0.288) 0.027(0.001 to 0.788) 0.027(0.001 to 0.788) 0.027(0.001 to 0.995) Verse variance weighted 2 0.011 0.038(0.185 to 0.801) 0.0387(0.980 to 0.995) Verse variance weighted 2 0.011 0.038(0.185 to 0.801) 0.0387(0.980 to 0.995) 0 1 2 0	SSOE elevision computer werage acceleration priving /PA	Asthma COPD PAH OSAS OSAS	Weighted median Inverse variance weighted Weighted median Inverse variance weighted Weighted median Inverse variance weighted Weighted median Inverse variance weighted Inverse variance weighted Weighted median	4 4 29 29 21 21 2 2 2 2 5 5 5	0.006 1.317e-06 0.002 1.282e-05 5.228e-05 0.003 0.033 0.033 0.039 0.011	0.991 (0.984 to 0.997) 0.985 (0.978 to 0.991) 0.986 (0.978 to 0.995) 1.718 (1.347 to 2.190) 1.805 (1.356 to 2.404) 0.017 (0.001 to 0.238) 0.022 (0.001 to 0.730) 0.511 (0.270 to 0.967)
SSOE         Asthma         Inverse variance weighted         4         1.317e-06         0.985(0.978 to 0.991)           Vergined median         4         0.002         0.986(0.978 to 0.991)         0.998(0.978 to 0.991)           Vergined median         29         5.228e-05         1.716(1.347 to 2.190)           Weighted median         21         0.033         0.017(0.001 to 0.288)           Verage acceleration         PAH         Inverse variance weighted         2         0.033         0.022(0.001 to 0.730)           Viring         OSAS         Inverse variance weighted         2         0.031         0.035(0.185 to 0.801)           Verage acceleration         PAH         Inverse variance weighted         2         0.001         0.335(0.185 to 0.801)           Verage acceleration         PAH         Inverse variance weighted         5         0.001         0.397(0.901 to 0.995)           Verage acceleration         PAH         Inverse variance weighted         5         0.001         0.397(0.901 to 0.995)           Verage acceleration         SA         Inverse variance weighted         5         0.001         0.937(0.901 to 0.995)           Verage acceleration         S         0.002         0         1         2	SSOE         Asthma         Inverse variance weighted         4         1.317e-06         0.985(0.978 to 0.991)           Islevision         COPD         Inverse variance weighted         2         0.002         0.0986(0.978 to 0.991)           Zamputer         PAH         Inverse variance weighted         2         0.003	SOE elevision computer verage acceleration priving /PA	Asthma COPD PAH OSAS OSAS	Inverse variance weighted Weighted median Inverse variance weighted Weighted median Inverse variance weighted Weighted median Inverse variance weighted Inverse variance weighted Weighted median	4 29 29 21 21 2 2 2 5 5 5	1.317e-06 0.002 1.282e-05 5.228e-05 0.003 ← 0.033 ← 0.039 ← 0.011 ←	0.985(0.978 to 0.991) 0.986(0.978 to 0.995) 1.718(1.347 to 2.190) 1.805(1.356 to 2.404) 0.017(0.001 to 0.238) 0.022(0.001 to 0.730) 0.511(0.270 to 0.967)
Meighted median       4       0.002       0.986(0.978 to 0.995)         Pelevision       COPD       Inverse variance weighted       29       1.282e-05       Image: Control to 0.238)         Computer       PAH       Inverse variance weighted       21       0.003       0.017(0.001 to 0.238)         Operation       COPD       Inverse variance weighted       2       0.039       0.017(0.001 to 0.238)         Vegetted median       21       0.003       Image: Control to 0.027(0.001 to 0.238)       0.022(0.001 to 0.238)         Vegetted median       21       0.039       Image: Control to 0.027(0.001 to 0.238)       0.022(0.001 to 0.238)         Vegetted median       25       0.001       0.985(0.185 to 0.801)       0.985(0.185 to 0.801)         /PA       OSAS       Inverse variance weighted       0.001       0.987(0.987) to 0.995)       0         //PA       OSAS       Inverse variance weighted       0.002       0.086(0.977 to 0.995)       0         //PA       OSAS       Inverse variance weighted       0.002       0.886(0.977 to 0.995)       0         //PA       OSAS       Inverse variance weighted       0.002       0.886(0.977 to 0.995)       0         //PA       OSAS       Inverse variance weighted       0.002       0.886(0.977 to	Prelevision         COPD         Inverse variance weighted         29         1.282e-05         →→→→→→→→→→→→→→→→→→→→→→→→→→→→→→→→→→→→	Television Computer Inverage acceleration Driving IPA	COPD PAH PAH OSAS OSAS	Weighted median Inverse variance weighted Weighted median Inverse variance weighted Weighted median Inverse variance weighted Inverse variance weighted Weighted median	4 29 21 21 2 2 2 2 5 5	0.002 1.282e-05 5.228e-05 0.003 0.033 0.039 0.011 0.001 0.001 0.001 0.001 0.003 0.005 0	0.986(0.978 to 0.995) 1.718(1.347 to 2.190) 1.805(1.356 to 2.404) 0.017(0.001 to 0.238) 0.022(0.001 to 0.730) 0.511(0.270 to 0.967)
COPD         Inverse variance weighted         29         1.282-05         ++++++++++++++++++++++++++++++++++	Television       COPD       Inverse variance weighted       29       1.282e-05       ++++++++++++++++++++++++++++++++++++	elevision Computer werage acceleration Driving /PA	COPD PAH OSAS OSAS	Inverse variance weighted Weighted median Inverse variance weighted Weighted median Inverse variance weighted Inverse variance weighted Inverse variance weighted Weighted median	29 29 21 21 2 2 5 5	1.282e-05 5.228e-05 0.003 ← 0.033 ← 0.039 ← 0.011 ← 0.011 ←	
Weighted median         29         5.228e-05         Image: Computer         PAH         Inverse variance weighted         21         0.003         Image: Computer         Out(7(0.001 to 0.238))         Out(2(0.011 to 0.238))         Out(2(0.011 to 0.238))         Out(2(0.011 to 0.238))         Image: Computer         PAH         Inverse variance weighted         2         0.033         Image: Computer         PAH         Inverse variance weighted         2         0.033         Image: Computer         Out(10.0138)         Image: Computer         Image: Computer	Weighted median         29         5.228-05         ++++++++++++++++++++++++++++++++++++	Computer werage acceleration )riving /PA	PAH OSAS OSAS	Weighted median Inverse variance weighted Weighted median Inverse variance weighted Inverse variance weighted Inverse variance weighted Weighted median	29 21 21 2 2 5 5	5.228e-05 0.003 0.033 0.039 0.011 	
Computer         PAH         Inverse variance weighted         21         0.003         ←         0.017(0.001 to 0.238)           Weighted median         21         0.003         ●         0.022(0.001 to 0.730)         0.022(0.001 to 0.730)           Weighted median         21         0.003         ●         ●         0.022(0.001 to 0.730)           Driving         CSAS         Inverse variance weighted         2         0.011         ●         0.987(0.980 to 0.995)           JPAH         OSAS         Inverse variance weighted         5         0.002	Computer       PAH       Inverse variance weighted 21       0.003       ←       0.017(0.001 to 0.238)         Weighted median       21       0.003       ←       0.022(0.001 to 0.238)         Nverage acceleration       PAH       Inverse variance weighted 2       0.001       0.017(0.001 to 0.238)         Driving       OSAS       Inverse variance weighted 2       0.001       0.017(0.001 to 0.238)         JPA       OSAS       Inverse variance weighted 5       0.001       0.0385(0.185 to 0.801)         JPA       OSAS       Inverse variance weighted 5       0.001       0.987(0.3901 to 0.995)         JPA       OSAS       Inverse variance weighted 5       0.001       0.987(0.3901 to 0.995)         JPA       OSAS       Inverse variance weighted 5       0.002       0.987(0.3901 to 0.995)         JPA       OSAS       Inverse variance weighted 5       0.002       0.987(0.3901 to 0.995)         JPA       OSAS       Inverse variance weighted 5       0.002       0.988(0.977 to 0.995)         JPA       OSAS       Inverse variance weighted 5       0.002       0.987(0.997 to 0.995)         JPA       JPA       OSAS       Inverse variance weighted 5       0.010         JPA       JPA       JPA       JPA       JPA <td>Computer Average acceleration Driving /PA</td> <td>PAH PAH OSAS OSAS</td> <td>Inverse variance weighted Weighted median Inverse variance weighted Inverse variance weighted Inverse variance weighted Weighted median</td> <td>21 21 2 2 5 5</td> <td>0.003 ••• 0.033 ••• 0.039 ••• 0.011 •••</td> <td>0.017(0.001 to 0.238) 0.022(0.001 to 0.730) 0.511(0.270 to 0.967)</td>	Computer Average acceleration Driving /PA	PAH PAH OSAS OSAS	Inverse variance weighted Weighted median Inverse variance weighted Inverse variance weighted Inverse variance weighted Weighted median	21 21 2 2 5 5	0.003 ••• 0.033 ••• 0.039 ••• 0.011 •••	0.017(0.001 to 0.238) 0.022(0.001 to 0.730) 0.511(0.270 to 0.967)
Weighted median 21 0.033 0.022(0.001 to 0.730) Inverse variance weighted 2 0.011 0.0385 0.0451 (0.270 to 0.987) Inverse variance weighted 5 0.001 0.386(0.977 to 0.995) Weighted median 5 0.002 0.886(0.977 to 0.995) 0 1 2	Weighted median 21 0.033 0.022(0.001 to 0.730) Inverse variance weighted 2 0.039 (PA OSAS Inverse variance weighted 5 0.001 0.986) Weighted median 5 0.002 0.986(0.977 to 0.998) 0.986(0.977 to 0.998) 0 1 2	Average acceleration Driving IPA	PAH OSAS OSAS	Weighted median Inverse variance weighted Inverse variance weighted Inverse variance weighted Weighted median	21 2 2 5 5	0.033 0.039 0.011	0.022(0.001 to 0.730) 0.511(0.270 to 0.967)
Nverage acceleration       PAH       Inverse variance weighted       2       0.039       0.511(0.270 to 0.967)         Jriving       OSAS       Inverse variance weighted       2       0.011       0.385(0.165 to 0.001)         JPA       OSAS       Inverse variance weighted       5       0.001       0.986(0.977 to 0.995)         Weighted median       5       0.002       0       1       2         0       1       2       0.011       0.986(0.977 to 0.995)         0       1       2       0.002       0       9         0       1       2       0.002       0       9       9         0       1       2       0       1       2       0       1       2	Nerrage acceleration         PAH         Inverse variance weighted         2         0.039         0.511(0.270 to 0.967)           Jriving         OSAS         Inverse variance weighted         2         0.011         0.987(0.977 to 0.995)           JPA         OSAS         Inverse variance weighted         5         0.002         0.996(0.977 to 0.995)           Verage acceleration         5         0.002         0.986(0.977 to 0.995)         0.996(0.977 to 0.995)	Average acceleration Driving IPA	PAH OSAS OSAS	Inverse variance weighted Inverse variance weighted Inverse variance weighted Weighted median	2 2 5 5	0.039 - 0.011 - •	0.511(0.270 to 0.967)
Driving OSAS Inverse variance weighted 2 0.01 0.385(0.185 to 0.801) /PA OSAS Inverse variance weighted 5 0.001 0.987(0.980 to 0.995) Weighted median 5 0.002 0 2 2 2 (0.977 to 0.995) 0 1 2 2 (0.977 to 0.995)	Driving OSAS Inverse variance weighted 2 0.01  OSAS Inverse variance weighted 5 0.001 PA OSAS Inverse variance weighted 5 0.001 O.385(0.155 to 0.30) Veighted median 5 0.002 O O O O O O O O O O O O O O O O O O	/PA	OSAS OSAS	Inverse variance weighted Inverse variance weighted Weighted median	2 5 5	0.011	0.011(0.210100.001)
OSAS       Inverse variance weighted 1       0.001       0.037(0.980 to 0.995)         Weighted median       5       0.002       0       0.997(to 0.995)         0       1       2       0       0       0	DSAS Inverse variance weighted 5 0.001 0.986(0.977 to 0.995) Weighted median 5 0.002 0.986(0.977 to 0.995)	/PA	OSAS	Inverse variance weighted Weighted median	5 5		0.385(0.185 to 0.801)
				Weighted median	5	0.001	0.987(0.980 to 0.995)
				gnou moulan	5	0.002	0 986(0 977 to 0 995)
						0.002	
						0	1 2